Dr. Franck-Emmanuel Nicolini   - CML  - LMC

The Hematology Department,
University Hospital Edouard Herriot,
Lyon, France 

VIDEOS in FRENCH

Les essais thérapeutiques et la LMC
15 avril 2015, LMC FRANCE

ARTICLES

CML stem cells: evasion for better invasion
2017, Journal Blood

Imatinib as Second-Line Therapy, Ameliorates or Maintains Molecular Responses Obtained with Ponatinib First-Line in Chronic Phase CML Patients
December 3, 2016, ASH 2016

Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)
November 26, 2011, Journal Blood

Imatinib plus Peginterferon Alfa-2a in Chronic Myeloid Leukemia
December 23, 2010, The New England Journal of Medicine

Evidence that Resistance to Nilotinib May Be Due to BCR-ABL, Pgp, or Src Kinase Overexpression
December 1, 2008, Cancer Research

ChemGenex Announces Positive Preliminary Data From Phase 2/3 Clinical Trial of Ceflatonin(R) at International Conference
October 1, 2007, Drugs.com

Announces Positive Preliminary Data From Phase 2/3 Clinical Trial of Ceflatonin(R) at International Conference
October 1, 2007, Drugs.com

         Voir les dernières nouvelles  sur la leucémie myéloïde chronique

         Voir CML experts in France